210 related articles for article (PubMed ID: 38534971)
1. The Conundrum of Cancer-Associated Thrombosis: Lesson Learned from Two Intriguing Cases and Literature Review.
Laurino S; Russi S; Omer LC; D'Angelo A; Bozza G; Gallucci G; Falco G; Roviello G; Bochicchio AM
Diseases; 2024 Feb; 12(3):. PubMed ID: 38534971
[TBL] [Abstract][Full Text] [Related]
2. Clinical Investigation of Hereditary and Acquired Thrombophilic Factors in Patients with Venous and Arterial Thromboembolism.
Kovács E; Bereczky Z; Kerényi A; Laczik R; Nagy V; Kovács DÁ; Kovács S; Pfliegler G
Int J Gen Med; 2023; 16():5425-5437. PubMed ID: 38021042
[TBL] [Abstract][Full Text] [Related]
3. Risk factors of arterial thrombotic events after unprovoked venous thromboembolism, and after cancer associated venous thromboembolism: A prospective cohort study.
Noumegni SR; Didier R; Mansourati V; Tromeur C; Le Moigne E; Hoffmann C; Nasr B; Gentric JC; Guegan M; Poulhazan E; Lacut K; Bressollette L; Le Mao R; Couturaud F
Thromb Res; 2022 Jun; 214():93-105. PubMed ID: 35525202
[TBL] [Abstract][Full Text] [Related]
4. Underlying Mechanisms of Thrombosis Associated with Cancer and Anticancer Therapies.
Pantazi D; Alivertis D; Tselepis AD
Curr Treat Options Oncol; 2024 Jun; ():. PubMed ID: 38862694
[TBL] [Abstract][Full Text] [Related]
5. High Incidence of Arterial and Venous Thrombosis in Antineutrophil Cytoplasmic Antibody-associated Vasculitis.
Kang A; Antonelou M; Wong NL; Tanna A; Arulkumaran N; Tam FWK; Pusey CD
J Rheumatol; 2019 Mar; 46(3):285-293. PubMed ID: 30385704
[TBL] [Abstract][Full Text] [Related]
6. Thrombotic risk of platinum combination chemotherapy with and without immune checkpoint inhibitors for advanced non-small cell lung cancer: a nationwide inpatient database study.
Iwai C; Jo T; Konishi T; Fujita A; Michihata N; Matsui H; Fushimi K; Yasunaga H
Cancer Immunol Immunother; 2023 Nov; 72(11):3581-3591. PubMed ID: 37540262
[TBL] [Abstract][Full Text] [Related]
7. Predictors of Recurrent Venous Thromboembolism or Arterial Thrombotic Events during and after Anticoagulation for a First Venous Thromboembolism.
Noumegni SR; Tromeur C; Hoffmann C; Mao RL; Moigne EL; Moreuil C; Mansourati V; Nasr B; Gentric JC; Guegan M; Poulhazan E; Bressollette L; Lacut K; Didier R; Couturaud F
Semin Thromb Hemost; 2023 Oct; 49(7):688-701. PubMed ID: 36252603
[TBL] [Abstract][Full Text] [Related]
8. Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer-a nationwide analysis.
Grilz E; Posch F; Nopp S; Königsbrügge O; Lang IM; Klimek P; Thurner S; Pabinger I; Ay C
Eur Heart J; 2021 Jun; 42(23):2299-2307. PubMed ID: 33769475
[TBL] [Abstract][Full Text] [Related]
9. Venous thromboembolism in cancer patients.
Deng A; Galanis T; Graham MG
Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
[TBL] [Abstract][Full Text] [Related]
10. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
[TBL] [Abstract][Full Text] [Related]
11. Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence.
Jiménez-Fonseca P; Gallardo E; Arranz Arija F; Blanco JM; Callejo A; Lavin DC; Costa Rivas M; Mosquera J; Rodrigo A; Sánchez Morillas R; Vares Gonzaléz M; Muñoz A; Carmona-Bayonas A
Eur J Intern Med; 2022 Jun; 100():33-45. PubMed ID: 35227541
[TBL] [Abstract][Full Text] [Related]
12. Decision support systems in clinical practice: The case of venous thromboembolism prevention.
Nazarenko GI; Kleymenova EB; Payushik SA; Otdelenov VA; Sychev DA; Yashina LP
Int J Risk Saf Med; 2015; 27 Suppl 1():S104-5. PubMed ID: 26639683
[TBL] [Abstract][Full Text] [Related]
13. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
[TBL] [Abstract][Full Text] [Related]
14. Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: A systematic review and meta-analysis.
Ortel TL; Meleth S; Catellier D; Crowther M; Erkan D; Fortin PR; Garcia D; Haywood N; Kosinski AS; Levine SR; Phillips MJ; Whitehead N
J Thromb Haemost; 2020 Sep; 18(9):2274-2286. PubMed ID: 32484606
[TBL] [Abstract][Full Text] [Related]
15. Are patients with thrombophilia and previous venous thromboembolism at higher risk to arterial thrombosis?
Linnemann B; Schindewolf M; Zgouras D; Erbe M; Jarosch-Preusche M; Lindhoff-Last E
Thromb Res; 2008; 121(6):743-50. PubMed ID: 17804043
[TBL] [Abstract][Full Text] [Related]
16. Increased risk of venous and arterial thromboembolism in patients with colorectal cancer receiving cetuximab-based combination chemotherapy: A population-based study in Korea.
Yhim HY; Lee J; Kim KH; Kim SA; Lee JY; Hwang HG; Hong J; Lee JO; Bang SM
Thromb Res; 2023 Nov; 231():50-57. PubMed ID: 37804738
[TBL] [Abstract][Full Text] [Related]
17. [Venous thrombo-embolism during immune-mediated thrombotic thrombocytopenic purpura is prevalent in patients with a prolonged treatment with therapeutic plasma exchange].
Benhamou Y; Sauvètre G; Grangé S; Veyradier A; Coppo P
Rev Med Interne; 2020 Dec; 41(12):809-813. PubMed ID: 32727695
[TBL] [Abstract][Full Text] [Related]
18. A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study.
Gerotziafas GT; Taher A; Abdel-Razeq H; AboElnazar E; Spyropoulos AC; El Shemmari S; Larsen AK; Elalamy I;
Oncologist; 2017 Oct; 22(10):1222-1231. PubMed ID: 28550032
[TBL] [Abstract][Full Text] [Related]
19. [HCF-ANMCO/AICPR/GIEC/ITAHFA/SICOA/SICP/SIMG/SIT Cardiological Societies Council Consensus document: Anticoagulant therapy in venous thromboembolism and atrial fibrillation of the patient with cancer. Current knowledge and new evidence].
Gulizia Chairperson MM; Parrini Co-Chairperson I; Colivicchi Co-Chairperson F; Bisceglia I; Caiazza F; Gensini GF; Mureddu GF; Santomauro M; Ageno W; Ambrosetti M; Aspromonte N; Barni S; Bellocci F; Caldarola P; Carletti M; De Luca L; Di Fusco SA; Di Lenarda A; Di Nisio M; Domenicucci S; Enea I; Francese GM; Lestuzzi C; Lucà F; Maurea N; Nassiacos D; Pedretti RFE; Pusineri E; Roscio G; Rossini R; Russo A; Volterrani M; Gabrielli Co-Chairperson D
G Ital Cardiol (Rome); 2020 Sep; 21(9):687-738. PubMed ID: 33094745
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors.
Ando Y; Hayashi T; Sugimoto R; Nishibe S; Ito K; Kawada K; Ikeda Y; Yamada S; Imaizumi K
Invest New Drugs; 2020 Aug; 38(4):1200-1206. PubMed ID: 31823160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
